Several studies suggest that atherosclerotic disease is not a focal disease restricted to culprit lesions in the intima of the arterial wall, but seems to act as a general disease affecting the entire cardiovascular system. Evolving research has lately focused on the atherosclerotic component in calcific aortic stenosis (AS) as it seems that the valve is affected in a pattern similar to that of the vasculature. The hope is therefore, that we someday in the management of patients with calcific AS can apply some of the same treatment strategies as in atherosclerotic vascular disease. This article reviews the pathophysiological mechanisms of calcific AS, reviews current clinical trials of statin use in aortic stenosis and reports on on-going trials, evaluating whether cholesterol lowering therapy can slow disease progression in different populations. Finally, we review if computerized tomography, biomarkers, and clinical characteristics such as left ventricular ejection fraction, can be useful in stratifying patients to potential benefit of statin therapy.
Introduction
Aortic valve disease is very common and associated with increased morbidity and mortality. It is divided into aortic stenosis (AS) and aortic regurgitation, AS being the most common with an overall prevalence of 2-3% in Western populations aged over 65 years. [Freeman et al. 2004 ] The etiology of AS can be divided into nonvalvular stenosis, seen in patients with hypertrophic obstructive cardiomyopathy, and valvular stenosis. Valvular stenosis can further be separated into congenital AS including the increasing stenosis of a bicuspid aortic valve, the rheumatic AS and, the most frequent in the Western world, calcific AS. AS is a disease continuum, but is arbitrarily divided by severity into mild, moderate, and severe. According to American College of Cardiology/American Heart Association guidelines on valvular disease, severe AS is characterized by valve area <1.0 cm 2 , a mean gradient greater than 40 mm Hg, or jet velocity greater than 4.0 m/s, and referred to as asymptomatic in absence of dyspnea, angina, and syncope [Bonow et al. 2006 ]. Current treatment of AS is aortic valve replacement (AVR) since the landmark paper of Ross and Braunwald. [Ross, Jr and Braunwald, 1968] . A study by Pellikka et al. followed 622 asymptomatic patients with isolated AS and jet velocity more than an annual risk of sudden death of ∼1%, 57% were referred for AVR, and 77% of untreated patients developed symptoms. Furthermore, they found the risk of developing symptoms and death was reduced at lower jet velocities, [Pellikka et al. 2005] confirmed in subsequent studies. [Rosenhek et al. 2000; Lester et al. 1998; Otto et al. 1997; Iivanainen et al. 1996 ]. Thus, sudden cardiac death in asymptomatic patients is relatively rare and the likelihood of developing symptoms has been correlated to AS severity. However, because of the great variation among patients with AS, some remain asymptomatic in spite of severe AS. After symptom-onset the average survival is shown to only 2-5 years without AVR. [Ross, Jr and Braunwald, 1968] . Therefore, the timing of AVR has largely been guided by symptom-development in spite of the fact that not much is known about which patients will develop symptoms, and consequently all are recommended biannual or annual follow-up with clinical examination.
Risk factors
There are several known risk factors pertaining to the development of calcific AS, such as hypertension, smoking, diabetes, metabolic syndrome and hypercholesterolemia. [Katz et al.2006; Stewart et al. 1997 ]. The risk factors are generally the same as for vascular atherosclerosis and the two diseases often coexists. However, it remains unknown which factor or combinations of these determine whether the disease occurs in the vasculature or in the valve. Prevalence and severity of calcific AS increases with age; the Helsinki age study found that severe AS was present in 2.9% of the age group 75-86 years. [Lindroos et al. 1993] . Calcific AS has been shown to be a major contributor to AVR, [Dawkins et al. 2008 ] and with increasing life expectancy and lifestyle changes, the incidence of calcific AS is likely to increase with subsequent rise in complications and costs.
Histopathology
Histopathological studies on excised valves in patients with AS, tricuspid valves and no prior history of rheumatic fever or endocarditis, show characteristic leaflet pathology with fibrosis, chronic inflammatory cellular infiltration, nodular calcification, and bone formation which is referred to as calcific AS. The changes seem to be of a progressive nature and advance over several years. Changes begin in small areas with lipid deposition, extravasation of inflammatory cells, endothelial disruption, and sub-endothelial thickening at the aortic side of the valve. These initial abnormalities are referred to as early lesions [Otto et al. 1994] . Early lesions advance into nodular calcification comprising of minerals and lipids leading to aortic valve sclerosis [Freeman and Otto, 2005] . The increasing nodular calcification starts at the free edge and eventually moves down the leaflet, stiffening the cusp, leading to AS [Freeman and Otto, 2005; Warren and Yong, 1997 ]. There is a significant association between the extent of aortic histopathology and hemodynamic variables, such as the valvular gradient. [Cote et al. 2007 ]. The histopathological changes mimic those of vascular atherosclerotic disease with lipid deposition, macrophages and T-cell infiltration, [O'Brien et al. 1996] although there are also differences like thrombosis. These findings has laid the basis for understanding calcific AS development as an active inflammatory process, resembling that of atherosclerosis rather than an un-modifiable degenerative process, as it once was thought to be.
Pathophysiological mechanisms
Papers published in basic science agree on the fundamental role of inflammation and endothelial dysfunction in development of atherosclerotic disease and hence calcific AS [Freeman and Otto, 2005] . However, there are discrepancies among models explaining how inflammation and endothelial dysfunction is initiated, sustained, and how it plays together with other features, such as angiogenesis, calcification, and fibrosis, observed in calcific AS. [Kuiper et al. 2007; Rajamannan et al. 2007; Mazzone et al. 2006; O'Brien, 2006; Mohler, III, 2004] . Epidemiological data indicate that development of calcific aortic valve disease depends on the 'right' combination of risk factors, in particular lifestyle related health problems, over a sufficient period of time. [Chan, 2003] . Several studies link dyslipidemia, including plasma levels of small dense low density lipoprotein (LDL) to lifestyle related metabolic changes [Eckel et al. 2005] . It is believed that circulating LDL which normally enter and leave the vascular and valvular tissue by trans-endothelial transport through an active vesicular LDLreceptor transport and passive non-vesicular diffusion begins to accumulate in the valve due to risk factors, mediating an increase in the amount of LDL particles transported across the endothelial barrier into the valve, where they become bound to proteoglycans. These retained particles are then secondarily oxidized and activated, possibly in the interstitial fluid and/or within lysosomes of macrophages present in the valve. After oxidation the macrophages, possibly by cell lysis, release the oxidized lipoproteins to the extracellular valvular tissue, [Wen and Leake, 2007] where they promote inflammation and calcification. This pattern is similar to the Response-to-Retention model proposed by Williams and Tabas for vascular atherosclerosis [Williams and Tabas, 1995] and to the hypothesis by Nordestgaard et al. proposing that accumulation of lipoprotein is due to a shift in the balance between influx, efflux, and degradation of lipoproteins in the arterial wall, caused by atherogenic risk factors [Nordestgaard and Nielsen, 1994] . However, both of these hypotheses have since been modified, as it seems plausible that lipoprotein retention is a selective process dependent on the size of the lipoproteins. Interest has in particular been devoted to the subclass small-dense LDL which, possibly due to their size, more readily can penetrate the 'leaky' barrier between blood and valvular tissue and thus infiltrate the valve. In addition, it is argued that small-dense LDL particles have an increased affinity for proteoglycans, and can therefore more easily become trapped and undergo oxidation [Tabas et al. 2007 ].
Review
These hypothesis, are further supported by clinical studies finding that small-dense LDL, is determining in the estimate of a patient's risk of calcific AS [Mohty et al. 2008; St Pierre et al. 2005] . The distribution of LDL particle size among patients could, therefore, in part explain why patients with normal or near normal LDL levels, exhibit differences in atherosclerotic morbidity. Aortic calcification has been proposed initiated by oxidation of the lipoproteins, due to inflammation mediated by oxidized LDL particles activating the endothelium through an effect in lectin-like ox-receptor-1 expressed on valvular endothelial cells [Cote et al. 2007 ]. Others argue for a combined role of LDL and the renin-angiotensin system in endothelial activation and that angiotensin converting enzyme has been found bound to LDL and macrophages in lesion [O'Brien, 2006] . Activated endothelial cells upgrade expression of adhesion molecules such as cellular cell adhesion molecule, which mediate the entry of inflammatory cells into the process [Blankenberg et al. 2003 ]. It is likely that attracted inflammatory cells, releases proinflammatory cytokines and triggers both an innate and specific immune response against material in the lesion which help sustain disease activity [Kuiper et al. 2007 ]. In addition, inflammatory cells brought to the atherosclerotic lesion, such as T-cells and monocytes, are shown to release angiogenetic factors under hypoxic conditions, [de Boer et al. 1999] which are likely to exist in valve lesions. This could explain the angiogenesis reported in calcific AS [Mazzone et al. 2006 ] and with others reporting neovessel endothelial cells as highly activated, possibly attracting additional inflammatory cells [O'Brien et al. 1996 ]. Angiogenesis could therefore in calcific AS, as in coronary atherosclerosis, be an additional factor that sustains the inflammatory process.
The link between oxidized LDL, endothelial dysfunction, and inflammation to stiffening of the valve is not clear. Animal models point to more than a few potential pathways, including extracellular bone matrix protein and nuclear factor-KB mediating endochondral ossification and transdifferentation of myofibroblasts to osteoblast-like cells [O'Brien, 2006; Rajamannan et al. 2005; Mohler, III, 2004] . In addition, the Lrp5/beta-catenin pathway was recently described as a means by which oxidized LDL directly can mediate osteoblastogenesis and new bone formation [Rajamannan et al. 2005 ].
Furthermore, it remains unclear what external factors are sufficient to trigger underlying mechanisms to evolvement of calcific AS, and to which extent genes themselves are a risk factor and/or determines patient susceptibility to external risk factors. The importance of genetic abnormalities as a sole risk factor was recently underlined by Garg, describing the role of NOTCH-1 mutations, in two families with bicuspid and aortic valve calcification. This has led to the hypothesis that NOTCH-1 haploinsufficiency could be one of maybe many genetic causes of aortic valve malformation and calcification [Garg, 2006] . However, there are still many unsolved questions in this area, in particular regarding the mutations with low penetrance, likely to remain undetected, but with a potentially important influence on disease progression of AS and also response to cholesterol lowering therapy. Furthermore, risk factors promoting AS in addition to their isolated effect extent may have additional or perhaps synergistic effect. One study has shown that patients suffering from diabetes mellitus and metabolic syndrome are at increased risk of developing calcific aortic valve disease, and that the relative risk of suffering from aortic valve calcification shows a graded linear relationship to number of metabolic syndrome components [Katz et al. 2006 ]. If the increasing prevalence of calcific AS in patients who suffer hypercholesterolemia complicated with lifestyle related co-morbidity is due to a synergic effect, LDL-independent pathways, genes, increased hypoxic conditions, altered inflammatory response, or other factors brought in play when suffering multiple health problems is not yet fully understood. In spite of lack of an exact human pathophysiological model for development of calcific AS, use of epidemiological data has shown an association between high concentration of LDL and developing calcific AS [Stewart et al. 1997 ]. In addition, there is, as discussed earlier, strong theoretical arguments supporting the role of LDL in initiating calcific AS. In particular, the fact that, lipid deposition is a known precursor of aortic valve calcification, has consequently led to several pharmacological trials, which investigate the effect of lowering cholesterol in patients with calcific AS. Hypotheses are that reducing cholesterol weakens the inflammatory activity and improves endothelial dysfunction in the valve, subsequently reducing disease progression and reducing or postponing the need for AVR.
Cholesterol lowering trials
When pharmacologically lowering cholesterol, statins are the drugs of choice. Effects of statins are among other presumed to be primarily caused by a direct inhibition of 3-hydroxy-3methylglutaryl-coenzyme A (HMG-CoA) reductase, which secondary lowers plasma LDL. Statins have additional lipid independent effect on atherosclerotic processes, which are referred to as pleiotropic effects. The existence of these additional effects became evident as statin trials showed earlier than expected benefits on cardiovascular disease. It has been hypothesized that these additional or concomitant effects are caused by antithrombotic and anti-inflammatory effects as well as antioxidation, plaque stabilization and endothelial wall relaxation resulting in lower intra-arterial pressure and increased blood flow [Mays and Dujovne, 2008; Selwyn, 2007] . It is likely that these effects are also involved AS, but as AS pathogenesis differentiates in some ways from vascular atherosclerosis. Pleiotropic effects in AS most likely also differentiate in some ways as i.e., thrombosis plays a key pathogenic role only in vascular atherosclerosis. A paper by Kizu et al. describes one possible pleiotropic effect of statins on valvular calcification, as they in vitro find that statin inhibits RhoA activation argued to induce calcification and alkaline phosphatases in human vascular smooth muscle cells mediating calcification of the aortic valve [Kizu et al. 2004] . In vitro models such as the one by Kizu et al. are likely to explain some of the unexpected effects seen in statin therapy. However, it is not known whether statins, or more direct inhibitors of these processes, in the future are likely to play a clinical role in the treatment of AS. Evolving evidence has, as discussed earlier, pointed to the importance of the LDL phenotypic distribution. It is known that the different statin agents, have dissimilar abilities in regards to altering the LDL subclasses [Rizzo and Berneis, 2006 ]. Furthermore, many patients continue to have cardiovascular events despite effective lowering of LDL. The different effects on LDL subclasses among statin agents could, therefore, be of potential clinical importance, but further data is needed for conclusions, in particular, concerning AS. Figure 1 displays the processes related to cholesterol and the possible mechanisms by which statins can counteract the progression of AS. Abundant data support statin effect in lowering plasma LDL and improving outcome in ischemic heart disease and thromboembolic stroke [O'Regan et al. 2008; Ward et al. 2007] . In contrast, little is known about how statins affect outcome in patients with calcific AS. Early trials find effect of lowering cholesterol in AS, but several flaws in study designs are pointed out, including low number of patients, retrospective trials, and the fact that statin therapy group in retrospective trials often consists of patients already receiving statin therapy for hypercholesterolemia. This has made extrapolation of data to clinical practice difficult. However, in recent years several prospective trials (Table 1) investigate the effect of lowering cholesterol in AS. The first well designed prospective randomized study (the SALTIRE study) included 134 AS patients followed up 25 months [Cowell et al. 2005 ]. This trial did not find that statin therapy was significantly associated with an improved outcome, and did not find that statin therapy was significantly associated with an improved outcome, even though cholesterol levels were reduced significantly, valve calcification rate in the statin-treated was not slower than in the placebo-controlled group. Several authors have given their interpretation of the results, some arguing that statins possibly do not have a great effect on calcific AS, while others point to possible flaws in power and other statistical calculations and/or the compilation of the SALTIRE population. In this regard, the SALTIRE power calculation has been discussed as some argue the patients in this study were not akin to the general population in regards to the frequency of bicuspid aortic valves [Chan and Teo, 2005] . Furthermore, there were a large number of patients not reaching 25 months follow-up. These findings consequently increase the risk that SALTIRE does not test a 'true' community-based AS population and could imply that the rate of yearly velocity progression used for the power calculation of this study is possibly not well suited. Furthermore, data from trial by Moura et al. suggests that it takes more than one year maybe even more before a reduction in aortic valve area is seen [Moura et al. 2007 ]. However, in the trial by Moura et al. only patients with hypercholesterolemia were treated with statin, whereas those not having a dyslipidemia were left untreated, thus, restricting conclusions to only dyslipidemic patients. Other authors argue that the findings in the SALTIRE study are likely due to the fact that patients generally suffer from high transvalvular gradients and that a high-transvalvular-gradient-valve is most likely to be so stiff, that a reduction in Review Vessel lumen A. Plasma LDL concentration, in particular small-dense LDL, correlates to the amount of LDL retained in extracellular matrix, mainly bound to proteoglycanes. D. Activated endothelium mediates extravasation of inflammatory cells into lesion. Macrophages then engulf and oxidize lipoproteins forming foam cells and mediating further inflammation. In addtion, inflammatory cells release pro-inflammatory cytokines and angiogenic factors which help sustain the inflammation. A self-enhancing proces is established.
C. Oxidized-LDL attracts inflammatory cells by activating the endothelium, possibly through endothelial expressed lectin-like ox-receptor-1. In addition, oxidized-LDL mediates osteoblastogenesis and extracellular matrix synthesis, which further increses the amount of retained LDL, possibly by Lrp5/beta-catenin pathway.
E. Valve fibroblasts are affected by both oxidized-LDL and pro-inflammatory cytokines, and undergo transdifferentation to osteoblast-like cells. These cells underlie valve calcification and bone formation beginning as aortic valve sclerosis. Furthermore, it is likely that the genetic imprint is important in determining the risk and speed of osteblastogenesis and thus valve stiffening Statin weakens the inflammatory response and thus endothelial activation, but a direct inprovement of endothelial dysfunction through pleiotropic effects i.e. RhoA inhibition is also possible. This subsequently decreases inflammatory cell recruitment. The figure also illustrates that most statin effects are caused by preventing further disease progression, indicating that effects of statin therapy are likely to be greater in early stage disease. This is further supported by the hypothesis that fibrosis, becomes increasingly important in the late stages and that statin does not have a great effect on the fibrotic process. However, the amount of retained lipoprotein is a constant balance between influx and efflux which is shifted towards efflux by statins. Statin therapy is therefore likely to mediate an efflux of some retained lipoproteins from the valve, implying that some reversibility of calcific AS exists. Abbreviations: LDL = low density lipoprotein, ACE = angiotensin converting enzyme, VCAM-1: vascular cell adhesion molecule-1, Lrp5 = lipoprotein receptor related protein 5. [Chan et al. 2007] . A randomized trial of intensive lipid-lowering therapy in calcific AS [Cowell et al. 2005] . Rosuvastatin affecting the aortic valve endothelium to slow progression of AS [Moura et al. 2007] . Simvastatin Ezetimibe in aortic stenosis [Rossebo et al. 2007] . Stop aortic stenosis [Griffin, 2007] . Effect of statin treatment on aortic valve and coronary calcification [Mohler, III et al. 2007] . Randomized study to evaluate the efficacy of fluvastatin on inflammatory markers in patients with aortic stenosis [Sanchez, 2006] . Statin therapy in asymptomatic aortic stenosis [Schuler, 2005] .
disease progression is likely to only have a minor impact on outcome [Bonow et al. 2006 ]. Furthermore, at least two recent studies argue that the relation between valve calcification and hemodynamic variables is curvilinear and becomes flat at later stages [Cote et al. 2007; Mohler, III et al. 2006 ]. Fibrosis could be likely to play a relative greater role in late stage disease progression. Most likely valve fibrosis is not dependent on the exact same mechanisms as valve calcification and could, therefore, have a different and perhaps less dependent lipid profile. More recently, a trial by Moura et al. in 121 patients with moderate to severe calcific AS, as the first, found that openlabel statin therapy significantly reduced annual progression of echocardiographic variables as aortic valve area, peak and mean aortic gradient left ventricular systolic and diastolic diameters as well as improved left ventricular ejection fraction compared to placebo beginning at approximately twelve months of treatment [Moura et al. 2007 ]. These data are further supported by Mohler et al . that in a similar study of 61 patients found that statin therapy reduced coronary artery calcification but not aortic valve calcification during one year of follow-up [Mohler, III et al. 2007] . A recent retrospective trial by Antonini-Canterin et al. of 259 patients, with a mean follow-up of 5.6 ± 3.2 years also supports this hypothesis finding that in two groups with equal risk factor distribution, statin therapy significantly reduced the rate of V max change in the subgroup suffering aortic sclerosis. Defined as increased leaflet thickness and echogenicity with a peak aortic velocity V max >1.5 and <2 m/s, during long time follow-up [Antonini-Canterin et al. 2005] .
Future studies
In order to conclude on the effect of statin treatment in AS, in particular on cardiovascular morbidity and mortality but also on AVR, it is therefore evident that larger randomized placebo-controlled trials with a range from low to higher transvalvular gradients, and long enough follow-up are needed. Several larger trials have since been designed and are currently collecting data. One of these is the The Effect of Statin Therapy (Atorvastatin) on the Progression of Calcific Valvular Aortic Stenosis (STOP-AS) trial from Cleveland Clinic, with 59 included patients, followed up for eight years. Primary outcome measures are rate of change in the aortic valve area as measured by transthoracic echocardiography and secondary outcome measures are rate of change in the aortic valve area measured by transthoracic echocardiography compared to that of historical controls. Rate of change in aortic valve area as measured by transthoracic echocardiography compared to standard of care group. Change in the mean and peak gradients across the aortic valve as measured by transthoracic echocardiography in the treated group compared to a historical control group.
The study is estimated to complete in June 2008 [Griffin, 2007] .
Another study, the Simvastatin Ezetimibe in Aortic Stenosis (SEAS) trial, from the Nordic countries, Ireland, Germany, and the United Kingdom is a prospective, double-blind, placebocontrolled, two-armed clinical trial to test the influence of the combination of simvastatin 40 mg and ezetimibe 10 mg therapy on the progression of calcified AS in patients with asymptomatic mild to moderate AS. Patients (n = 1873) are followed for 4-5 years. Primary outcome measures are a composite of AVR and cardiovascular morbidity and mortality. Secondary outcome measurements include progression of calcific AS measured by transthoracic echocardiography (P max/mean ; V max ; aortic valve area, left ventricular function, compliance).
The study is to report at the American Heart Association meeting in November 2008 [Rossebo et al. 2007] .
A study, the Statin Therapy in Asymptomatic Aortic Stenosis study, from University of Leipzig, Germany is a prospective, double-blind, placebo-controlled, two-armed clinical trial to test the influence of statin therapy on the progression of calcified AS in patients with asymptomatic mild to moderate AS. Patients (n = 100) are randomly assigned to fluvastatin 40 mg/day or to the placebo-control and followed for 24 months. Primary outcome measures are progression of calcific AS measured by transthoracic echocardiography (P max/mean ; V max ; AVA), catheterization (peak to peak gradient, left ventricular function, compliance) and secondary outcome measurements are number of cardiovascular events. The study is projected to terminate in December 2008 [Schuler, 2005] .
A fourth study is The Aortic Stenosis Progression observer: Measuring Effects Rosuvastatin (ASTRONOMER) trial, from Canada is a prospective, double blind, placebo-controlled, Review two armed clinical trial including patients (n = 272) with moderate to severe AS. The primary objective is to determine whether patients assigned to Rosuvastatin 40 mg/day will experience less progression in transvalvular gradients and valve areas compared to placebo. Secondary objectives are to determine effect of Rosuvastatin on the rate of cardiac death and AVR and to assess the time to outcome during a follow-up of 3-5 years. This study has terminated and plans to presents data by the end of 2008 [Chan et al. 2007] .
A final study, called Randomized Study to Evaluate the Efficacy of Fluvastatin on Inflammatory Markers in Patients with AS is a prospective, phase IV-III, randomized, double blind, active controlled study, to evaluate the efficacy of fluvastatin on inflammatory markers in the hemodynamic progression of degenerative AS.
Hypotheses are that statins therapy decrease inflammatory markers concentrations in patients with degenerative AS and halt the hemodynamic progression of the disease. Eligible patients with degenerative AS will be randomized 1 : 1 to fluvastatin 80 mg once daily or placebo and follow-up for twelve months. Primary outcome measures are changes in C-reactive protein concentration at study end. Secondary outcome measures are changes in other inflammatory biomarkers from baseline to twelve months, changes in these biomarkers in the different grades of AS and changes in aortic valve area and medium aortic transvalvular gradient at the end of the study as well as safety and tolerability of fluvastatin. The study is to complete in November 2008 [Sanchez, 2006] .
Discussion and future perspectives
There are theoretical and epidemiological arguments that indicate statin therapy in calcific AS is potentially effective. However, trials published so far have low power, are open label, small sample size, and have had too short duration to expect an effect on AS and deviate both in favor of and against statins, making conclusions at this time uncertain. Several large trials present data this year and will enhance our knowledge on the benefit from statin. Based on our current understanding of calcific AS, there is, however, an acceptance that statin therapy should be initiated as early as possible to achieve optimal effect. This understanding indicates that the effect of statin therapy, at least in late stage aortic valve atherosclerosis, is most likely different from that of coronary atherosclerosis. This presumption points towards outcome in patients with valve atherosclerosis depending on other mechanisms than in patients with coronary atherosclerosis, one potential mechanism could be thrombosis.
In coronary atherosclerosis there is not applied any greater load on the cardiovascular system until plaque rupture, statins will therefore through a reduction in the risk of plaque rupture greatly improve outcome. In comparison, it is likely that thrombosis is not involved progression of calcific AS [Mazzone et al. 2006 ], but there is instead a continuous obstruction of the left ventricle. This causes permanent left ventricular strain and flow abnormalities, which potentially independent of statin therapy could increase the risk of cardiovascular morbidity and mortality. Furthermore, it is likely that both left ventricular remodeling as a consequence of AS, as well as the induced valvular histopathological changes are likely to 'normalize' slowly. In calcific AS patients starting statin therapy, there is, therefore, likely to be a prolonged period with risk of myocardial ischemia and arrhythmia caused by hypertrophy-induced increased myocardial oxygen consumption and possible imbalance between oxygen supply and demand, as well as valvular obstruction due to more or less 'permanent' fibrotic changes. In spite of lacking knowledge about the differences in processes, an early start of statin therapy in calcific AS is made difficult by the fact that most symptoms appear in late stage disease. A typical case scenario is that a systolic murmur is heard and an echocardiogram is performed to verify the diagnosis. Several studies have shown a reliable prognostic value of echocardiography and an additional cardiac catheterization is, therefore, only performed when special indications to evaluate the hemodynamic severity occur. However, none of the tests currently available to physicians provide much information about the role of cholesterol in the present stage of the disease process. When presented with a patient it is, therefore, difficult for the treating physician to determine who will benefit most from statin therapy. Evolving research shows that in patients diagnosed with calcific AS, computerized tomography measured degree of valve calcification can provide valuable information, as it is shown that this quantification of valve calcification degree correlates well with histopathological changes and prognosis [Messika-Zeitoun et al. 2004 ]. In addition, computerized tomography can predict aortic valve areas, left ventricular ejection fraction, and the coronary artery anatomy, providing a general assessment of the cardiovascular system [Laissy et al. 2007 ]. As described earlier, the computerized tomography measured calcification is curvilinear to aortic valve area becoming flat in late stages, [Mohler, III et al. 2006] indicating that fibrosis plays a relative greater role in late stage AS. It is not well investigated whether new computerized tomography software allowing for a measurement of the fibrotic component can provide cut-off calcification values, where effect of statin therapy is likely to be insignificant. It should, however, be stated that computerized tomography is still only complementary to the prognostic information provided by echocardiography. Other studies find that biomarkers such as high sensitivity C-reactive-protein and N-terminal pro brain natriuretic peptide also can be useful in determining progression rate, severity, and outcome in patients with calcific AS Weber et al. 2006 ]. The potential role of biomarkers are also investigated in some of large randomized trial, as described earlier, hypothesizing similar correlation to disease progression. However, some studies have not found a similar correlation between blood level CRP and AS [Novaro et al. 2007] . A combined risk score using biomarkers and computerized tomography will therefore, until further data is available, only hypothetically allow for a more complete assessment in each patient and thus a better estimate of who will benefit from cholesterol lowering therapy versus AVR. Furthermore, as calcific AS is a presentation of atherosclerosis, quite a few patients also have atherosclerotic affection of other organs and vasculature. The effect of statins in calcific AS is, therefore, also likely to be dependent on the composition of other organ affection. It is known that aortic ostial area is dependent of flow and in AS patients with reduced left ventricular ejection fraction, perhaps following a coronary event, the outcome is poorer than in control groups [Martinez and Nishimura, 2006; Shively et al. 1998 ]. Statin therapy could, therefore, in some settings have a greater effect on i.e., the ostial area, than in control group with equal transvalvular gradient, caused by a reduction in coronary disease even if the severity of the AS normally should indicate little statin effect. Future studies must investigate the effect of statin therapy in these different populations and additionally whether pleiotropic effects of statin and/or an alteration of LDL subclasses can be useful in treating patients with normal lipids developing calcific AS.
